PriceTargets.com logo

NightHawk Biosciences - NHWK Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 02/6/2024 12:59 AM ET
+0 (0.00%)
Get New NightHawk Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NHWK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NHWK

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for NightHawk Biosciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for NHWK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in NightHawk Biosciences. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2023Maxim GroupDowngradeBuy ➝ HoldLow
3/18/2022B. RileyLower TargetBuy$10.00 ➝ $8.00High
3/15/2022Cantor FitzgeraldReiterated RatingOverweightHigh
1/24/2022B. RileyLower Target$15.00 ➝ $10.00Low
11/12/2021Maxim GroupInitiated CoverageBuy$15.00High
8/25/2021Alliance Global PartnersLower TargetBuy$32.00 ➝ $20.00Low
8/18/2021B. RileyBoost TargetBuy$15.00 ➝ $20.00High
5/6/2021Alliance Global PartnersLower Target$40.00 ➝ $32.00High
3/2/2021Cantor FitzgeraldInitiated CoverageOverweight$22.00High
2/9/2021Alliance Global PartnersBoost TargetPositive ➝ Buy$5.00 ➝ $40.00Low
2/9/2021Maxim GroupReiterated RatingBuy$14.00Low
12/24/2020B. RileyReiterated RatingBuyN/A
12/3/2020B. RileyReiterated RatingBuy$28.00Low
10/14/2020B. RileyReiterated RatingBuyMedium
10/14/2020B. RileyInitiated CoverageBuy$28.00 ➝ $28.00Low
6/19/2020Maxim GroupInitiated CoverageBuy$14.00Low
5/15/2020Maxim GroupInitiated CoverageBuy$14.00Low
4/1/2020Maxim GroupReiterated RatingBuy$14.00Medium
3/5/2020Maxim GroupBoost Target$7.00 ➝ $14.00High
3/3/2020Maxim GroupReiterated RatingBuy$7.00High
2/6/2020Maxim GroupInitiated CoverageBuyHigh
7/29/2019Brookline Capital ManagementInitiated CoverageBuy$56.00 ➝ $56.00High
5/17/2019Alliance Global PartnersSet TargetBuy$42.00Medium
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
NightHawk Biosciences logo
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.39
Low: $0.26
High: $0.50

52 Week Range

Now: N/A

Volume

173,100 shs

Average Volume

97,242 shs

Market Capitalization

$10.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19

Frequently Asked Questions

What sell-side analysts currently cover shares of NightHawk Biosciences?

The following Wall Street sell-side analysts have issued reports on NightHawk Biosciences in the last year:
View the latest analyst ratings for NHWK.

What is the current price target for NightHawk Biosciences?

0 Wall Street analysts have set twelve-month price targets for NightHawk Biosciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for NightHawk Biosciences in the next year.
View the latest price targets for NHWK.

What is the current consensus analyst rating for NightHawk Biosciences?

NightHawk Biosciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NHWK.

What other companies compete with NightHawk Biosciences?

Other companies that are similar to NightHawk Biosciences include Eterna Therapeutics, Galera Therapeutics, Guardion Health Sciences, Moleculin Biotech and Monopar Therapeutics. Learn More about companies similar to NightHawk Biosciences.

How do I contact NightHawk Biosciences' investor relations team?

NightHawk Biosciences' physical mailing address is 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560. The biopharmaceutical company's listed phone number is 919-240-7133 and its investor relations email address is [email protected]. The official website for NightHawk Biosciences is www.nighthawkbio.com. Learn More about contacing NightHawk Biosciences investor relations.